tiprankstipranks
Trending News
More News >
Abbott Laboratories (ABT)
NYSE:ABT
US Market
Advertisement

Abbott Laboratories (ABT) Stock Forecast & Price Target

Compare
8,629 Followers
See the Price Targets and Ratings of:

ABT Analyst Ratings

Strong Buy
19Ratings
Strong Buy
16 Buy
3 Hold
0 Sell
Based on 19 analysts giving stock ratings to
Abbott
Laboratories
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ABT Stock 12 Month Forecast

Average Price Target

$145.17
▲(15.54%Upside)
Based on 19 Wall Street analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is $145.17 with a high forecast of $159.00 and a low forecast of $135.00. The average price target represents a 15.54% change from the last price of $125.64.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"99":"$99","160":"$160","114.25":"$114.3","129.5":"$129.5","144.75":"$144.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":159,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$159.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":145.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$145.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$135.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[99,114.25,129.5,144.75,160],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,135.65,137.44615384615386,139.2423076923077,141.03846153846155,142.83461538461538,144.63076923076923,146.4269230769231,148.22307692307692,150.01923076923077,151.81538461538463,153.61153846153846,155.40769230769232,157.20384615384614,{"y":159,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,135.65,136.3823076923077,137.11461538461538,137.84692307692308,138.57923076923078,139.31153846153845,140.04384615384615,140.77615384615385,141.50846153846155,142.24076923076922,142.97307692307692,143.70538461538462,144.4376923076923,{"y":145.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,135.65,135.6,135.55,135.5,135.45000000000002,135.4,135.35,135.3,135.25,135.2,135.15,135.1,135.05,{"y":135,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":100.72,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.07,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.13,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.42,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.77,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.76,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$159.00Average Price Target$145.17Lowest Price Target$135.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ABT
TipRanks AITipRanks
Not Ranked
TipRanks
$134
Buy
6.65%
Upside
Reiterated
07/18/25
Abbott Laboratories achieves a solid overall stock score driven by strong financial performance and positive earnings call insights. While the technical analysis indicates bearish momentum, the company's robust financial health and strategic growth initiatives in key segments support its long-term prospects. The valuation remains fair, providing a balanced investment opportunity.
Wells Fargo Analyst forecast on ABT
Larry BiegelsenWells Fargo
Wells Fargo
$151$142
Buy
13.02%
Upside
Reiterated
07/21/25
Analysts' Top Healthcare Picks: Jazz Pharmaceuticals (JAZZ), Abbott Laboratories (ABT)
Leerink Partners Analyst forecast on ABT
Mike KratkyLeerink Partners
Leerink Partners
$143$136
Hold
8.25%
Upside
Reiterated
07/21/25
Abbott Laboratories: Hold Rating Amid Mixed Performance and Sector Challenges
UBS
$148
Buy
17.80%
Upside
Reiterated
07/21/25
UBS Remains a Buy on Abbott Laboratories (ABT)UBS analyst Danielle Antalffy reiterated a Buy rating and $148.00 price target on Abbott Labs (NYSE: ABT).
Raymond James Analyst forecast on ABT
Jayson BedfordRaymond James
Raymond James
$142$141
Buy
12.23%
Upside
Reiterated
07/18/25
Abbott price target lowered to $141 from $142 at Raymond JamesAbbott price target lowered to $141 from $142 at Raymond James
Oppenheimer Analyst forecast on ABT
Suraj KaliaOppenheimer
Oppenheimer
$140
Buy
11.43%
Upside
Reiterated
07/18/25
Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (NASDAQ: GANX), Abbott Laboratories (NYSE: ABT) and ANI Pharmaceuticals (NASDAQ: ANIP)
Citi
$157$155
Buy
23.37%
Upside
Reiterated
07/18/25
Citi Keeps Their Buy Rating on Abbott Laboratories (ABT)
Jefferies
$145
Buy
15.41%
Upside
Upgraded
07/18/25
Abbott upgraded to Buy from Hold at JefferiesAbbott upgraded to Buy from Hold at Jefferies
Barclays Analyst forecast on ABT
Matt MiksicBarclays
Barclays
$159
Buy
26.55%
Upside
Reiterated
07/18/25
Analysts Offer Insights on Healthcare Companies: Elevance Health (NYSE: ELV), Tarsus Pharmaceuticals (NASDAQ: TARS) and Abbott Laboratories (NYSE: ABT)
Bank of America Securities Analyst forecast on ABT
Travis SteedBank of America Securities
Bank of America Securities
$150
Buy
19.39%
Upside
Reiterated
07/18/25
Buy Rating on Abbott Laboratories: Attractive Valuation Amid Growth Prospects and Market Overreaction
Mizuho Securities Analyst forecast on ABT
Anthony PetroneMizuho Securities
Mizuho Securities
$140$135
Hold
7.45%
Upside
Reiterated
07/18/25
Mizuho Securities Remains a Hold on Abbott Laboratories (ABT)
Stifel Nicolaus Analyst forecast on ABT
Rick WiseStifel Nicolaus
Stifel Nicolaus
$145
Buy
15.41%
Upside
Reiterated
07/18/25
Stifel Nicolaus Keeps Their Buy Rating on Abbott Laboratories (ABT)
TD Cowen
$145
Buy
15.41%
Upside
Reiterated
07/17/25
Abbott Laboratories: Strong Medical Devices Performance and Resilient Growth Amid Challenges
BTIG
$148$145
Buy
15.41%
Upside
Reiterated
07/17/25
BTIG Remains a Buy on Abbott Laboratories (ABT)
Goldman Sachs Analyst forecast on ABT
David RomanGoldman Sachs
Goldman Sachs
$153
Buy
21.78%
Upside
Reiterated
07/17/25
Goldman Sachs Sticks to Their Buy Rating for Abbott Laboratories (ABT)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ABT
TipRanks AITipRanks
Not Ranked
TipRanks
$134
Buy
6.65%
Upside
Reiterated
07/18/25
Abbott Laboratories achieves a solid overall stock score driven by strong financial performance and positive earnings call insights. While the technical analysis indicates bearish momentum, the company's robust financial health and strategic growth initiatives in key segments support its long-term prospects. The valuation remains fair, providing a balanced investment opportunity.
Wells Fargo Analyst forecast on ABT
Larry BiegelsenWells Fargo
Wells Fargo
$151$142
Buy
13.02%
Upside
Reiterated
07/21/25
Analysts' Top Healthcare Picks: Jazz Pharmaceuticals (JAZZ), Abbott Laboratories (ABT)
Leerink Partners Analyst forecast on ABT
Mike KratkyLeerink Partners
Leerink Partners
$143$136
Hold
8.25%
Upside
Reiterated
07/21/25
Abbott Laboratories: Hold Rating Amid Mixed Performance and Sector Challenges
UBS
$148
Buy
17.80%
Upside
Reiterated
07/21/25
UBS Remains a Buy on Abbott Laboratories (ABT)UBS analyst Danielle Antalffy reiterated a Buy rating and $148.00 price target on Abbott Labs (NYSE: ABT).
Raymond James Analyst forecast on ABT
Jayson BedfordRaymond James
Raymond James
$142$141
Buy
12.23%
Upside
Reiterated
07/18/25
Abbott price target lowered to $141 from $142 at Raymond JamesAbbott price target lowered to $141 from $142 at Raymond James
Oppenheimer Analyst forecast on ABT
Suraj KaliaOppenheimer
Oppenheimer
$140
Buy
11.43%
Upside
Reiterated
07/18/25
Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (NASDAQ: GANX), Abbott Laboratories (NYSE: ABT) and ANI Pharmaceuticals (NASDAQ: ANIP)
Citi
$157$155
Buy
23.37%
Upside
Reiterated
07/18/25
Citi Keeps Their Buy Rating on Abbott Laboratories (ABT)
Jefferies
$145
Buy
15.41%
Upside
Upgraded
07/18/25
Abbott upgraded to Buy from Hold at JefferiesAbbott upgraded to Buy from Hold at Jefferies
Barclays Analyst forecast on ABT
Matt MiksicBarclays
Barclays
$159
Buy
26.55%
Upside
Reiterated
07/18/25
Analysts Offer Insights on Healthcare Companies: Elevance Health (NYSE: ELV), Tarsus Pharmaceuticals (NASDAQ: TARS) and Abbott Laboratories (NYSE: ABT)
Bank of America Securities Analyst forecast on ABT
Travis SteedBank of America Securities
Bank of America Securities
$150
Buy
19.39%
Upside
Reiterated
07/18/25
Buy Rating on Abbott Laboratories: Attractive Valuation Amid Growth Prospects and Market Overreaction
Mizuho Securities Analyst forecast on ABT
Anthony PetroneMizuho Securities
Mizuho Securities
$140$135
Hold
7.45%
Upside
Reiterated
07/18/25
Mizuho Securities Remains a Hold on Abbott Laboratories (ABT)
Stifel Nicolaus Analyst forecast on ABT
Rick WiseStifel Nicolaus
Stifel Nicolaus
$145
Buy
15.41%
Upside
Reiterated
07/18/25
Stifel Nicolaus Keeps Their Buy Rating on Abbott Laboratories (ABT)
TD Cowen
$145
Buy
15.41%
Upside
Reiterated
07/17/25
Abbott Laboratories: Strong Medical Devices Performance and Resilient Growth Amid Challenges
BTIG
$148$145
Buy
15.41%
Upside
Reiterated
07/17/25
BTIG Remains a Buy on Abbott Laboratories (ABT)
Goldman Sachs Analyst forecast on ABT
David RomanGoldman Sachs
Goldman Sachs
$153
Buy
21.78%
Upside
Reiterated
07/17/25
Goldman Sachs Sticks to Their Buy Rating for Abbott Laboratories (ABT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Abbott Laboratories

1 Month
xxx
Success Rate
26/37 ratings generated profit
70%
Average Return
+2.47%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 70.27% of your transactions generating a profit, with an average return of +2.47% per trade.
3 Months
xxx
Success Rate
22/28 ratings generated profit
79%
Average Return
+4.88%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 78.57% of your transactions generating a profit, with an average return of +4.88% per trade.
1 Year
Rick WiseStifel Nicolaus
Success Rate
23/26 ratings generated profit
88%
Average Return
+15.84%
reiterated a buy rating 8 days ago
Copying Rick Wise's trades and holding each position for 1 Year would result in 88.46% of your transactions generating a profit, with an average return of +15.84% per trade.
2 Years
xxx
Success Rate
19/24 ratings generated profit
79%
Average Return
+13.22%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 79.17% of your transactions generating a profit, with an average return of +13.22% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABT Analyst Recommendation Trends

Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
0
0
0
0
0
Buy
33
41
49
42
44
Hold
2
3
3
4
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
35
44
52
46
48
In the current month, ABT has received 44 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. ABT average Analyst price target in the past 3 months is 145.17.
Each month's total comprises the sum of three months' worth of ratings.

ABT Financial Forecast

ABT Earnings Forecast

Next quarter’s earnings estimate for ABT is $1.30 with a range of $1.28 to $1.37. The previous quarter’s EPS was $1.26. ABT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.65% of the time in the same period. In the last calendar year ABT has Outperformed its overall industry.
Next quarter’s earnings estimate for ABT is $1.30 with a range of $1.28 to $1.37. The previous quarter’s EPS was $1.26. ABT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.65% of the time in the same period. In the last calendar year ABT has Outperformed its overall industry.

ABT Sales Forecast

Next quarter’s sales forecast for ABT is $11.40B with a range of $11.17B to $11.50B. The previous quarter’s sales results were $11.14B. ABT beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 53.04% of the time in the same period. In the last calendar year ABT has Outperformed its overall industry.
Next quarter’s sales forecast for ABT is $11.40B with a range of $11.17B to $11.50B. The previous quarter’s sales results were $11.14B. ABT beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 53.04% of the time in the same period. In the last calendar year ABT has Outperformed its overall industry.

ABT Stock Forecast FAQ

What is ABT’s average 12-month price target, according to analysts?
Based on analyst ratings, Abbott Laboratories’s 12-month average price target is 145.17.
    What is ABT’s upside potential, based on the analysts’ average price target?
    Abbott Laboratories has 15.54% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ABT a Buy, Sell or Hold?
          Abbott Laboratories has a consensus rating of Strong Buy which is based on 16 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Abbott Laboratories’s price target?
            The average price target for Abbott Laboratories is 145.17. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $159.00 ,the lowest forecast is $135.00. The average price target represents 15.54% Increase from the current price of $125.64.
              What do analysts say about Abbott Laboratories?
              Abbott Laboratories’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of ABT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis